Opdivo’s commercial potential will likely take a hit in the wake of new Keytruda data, but the impact may depend on the ability of BMS to market the message that its I-O/I-O combo allows patients to delay chemo.
Five things for pharma marketers to know: Tuesday, May 1, 2018
Fitbit partners with Google Cloud to make health data more shearable; Regeneron, Sanofi to slash price of Praluent for Express Scripts customers; Novo Nordisk teams up with startup to help diabetes patients.
Five things for pharma marketers to know: Monday, April 30, 2018